Journals / Uluslararası Hematoloji-Onkoloji Dergisi / 2010 / Cilt: 20 - Sayı: 1

Malign plevral mezotelyomalı olgularda ekstra plevral pnömonektomi sonrası hemitorasik radyoterapinin etkinliği ve toksisitesi

The efficiency and toxicity of hemithoracic radiotherapy after extra pleural pneumonectomy in malign pleural mesothelioma

Pages
20–26
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

More effective systemic treatment is needed to prevent the recurrences outside thorax.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In this study, we evaluated the efficiency and the toxicity of three dimensional conformal hemithoracic radiotherapy (3DCHRT) after extra pleural pneumonectomy (EPP).
📊
Key Findings & Data:The median age of 14 patients were 51 years (range, 33-61 years).
💡
Conclusion & Impact:More effective systemic treatment is needed to prevent the recurrences outside thorax.
🔬Design:Research Article
📍Scope:2002 Verileri
⚙️Variables:Domain Parameters

Abstract

In this study, we evaluated the efficiency and the toxicity of three dimensional conformal hemithoracic radiotherapy (3DCHRT) after extra pleural pneumonectomy (EPP). The median age of 14 patients were 51 years (range, 33-61 years). Most commonly seen histopathology was epitheliod type (79%). According to American Joint Commission on Cancer (AJCC) 2002 staging system 9 cases (64%) were stage III. A total median dose of 50.4 Gy was applied to hemithoracic cavity. Eleven patients received adjuvant chemotherapy. 3DCHRT was generally well tolerated. The acute toxicities of 3DCHRT were grade I-II. After a median of 16 months follow-up, intrathoracic control was100%. Six patients (43%) developed abdominal relapse and one (7%) developed distant metastasis. Nine cases were dead with two of them being without the evidence of disease. Excellent local control with 3DCHRT after EPP seems to change the relapse patterns of MPM. More effective systemic treatment is needed to prevent the recurrences outside thorax.

Özet

Bu çalışma kapsamında EPP sonrası üç boyutlu konformal eksternal radyoterapinin (3BKRT) etkinlik ve toksisitesinin değerlendirilmesi hedeflenmiştir. En sık görülen histopatoloji epitelyal tipti (%79). American Joint Commission on Cancer (AJCC) 2002 evreleme sistemine göre bir olgu (%7) evre I, 4 olgu (%29) evre II, 9 olgu (%64) evre III olarak kabul edildi. Hemitoraksa 1.8 Gy/ gün fraksiyon dozu ile toplam medyan 50.4 Gy 3BKRT uygulandı. Onbir hasta platin ve pemetreksed kombinasyonundan oluşan adjuvan kemoterapi aldı. Radyoterapi (XRT) sırasında gözlemlenen akut toksisiteler grad I-II olup tedavi iyi tolere edilmiştir. Medyan 16 aylık izlem sonucu lokal kontrol %100’dü. Hastaların 6’sında (%43) abdominal relaps, birinde (%7) uzak metastaz gelişti. İkisi hastalık dışı nedenlerle olmak üzere 9 olgu (%64) kaybedildi. 3BKRT ile lokal kontrolün sağlanması relaps şeklini değiştirmiş görünmektedir. Toraks dışı relapsların önlenememesi daha etkin sistemik tedavi gerekliliğini düşündürmektedir.

🔖

Cite This Article

HÜRMÜZ, P., AKYOL, F., SELEK, U., ÖZYİĞİT, G., DOĞAN, R., ÖZDEMİR, N., TAŞTEPE, İ., CANGIR, A. K., KARA, M., DEMİRKAZIK, F. B., EMRİ, S. (2010). Malign plevral mezotelyomalı olgularda ekstra plevral pnömonektomi sonrası hemitorasik radyoterapinin etkinliği ve toksisitesi. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 20 - Sayı: 1, 20–26. https://ajindex.com/articles/322993

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Rusch.VW, Mesothelioma and less common pleural tumours. In: Pearson FG and Cooper JD (Eds): ‘Thoracic Surgery’, 2nd edn. Philadelphia, PA: Churchill Li- vingstone 2002: 1241-1263
  2. Pass HI, Hahn SM, Vogelzang NJ, Carbone M. Benign and malignant mesothelioma. In: De Vita VT Jr, Hellman S, Rosenberg SA (Eds): Cancer: Principles and Practice of Oncology, 7th edn. Lippincott Williams & Wilkins, Philadelphia, 2001: 1937-1964
  3. Vogelzang NJ, Rusthoven JJ, Symanovski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21: 2636-2644, 2003. 4. van Meerbeeck JP, Gaafar R, Manegold C, et al. European Organisation for Research and Treatment of Cancer Lung Cancer Group; National Cancer Institute of Canada. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23: 6881-6889, 2005
  4. Rusch VW, Rosenweig K, Venkatraman E, et al. A phase II trial of surgical resection and adjuvant high dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 122: 788-795, 2001
  5. Law MR, Gregor A, Hodson ME, et al. Malignant pleural mesothelioma of the pleura: a sudy of 52 treated and 64 untreated patients. Thorax 39: 255-259, 1984
  6. Baldini EH, Recht A, Strauss GM, et al. Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 63: 334-338, 1997
  7. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 117: 54-65, 1999
  8. Flores RM, Krug LM, Rosenzweig KE, et al. Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: A phase II trial. J Thorac Oncol 1: 289-295, 2006
  9. Weder W, Kestenholz P, Taverna C, et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol 22: 3451-3457, 2004
  10. Weder W, Stahel RA, Bernhard J, et al. Swiss Group for Clinical Cancer Research. Multicenter trial of neoadjuvant chemotherapy followed by extrapleural